News
![IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update
IMV Inc. (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the third quarter
![QIAGEN stellt auf der AMP-Jahreskonferenz 2019 einen neuen NGS-Workflow für die simultane DNA- und RNA-Analyse zum Einsatz im Krebs-Profiling vor](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
QIAGEN stellt auf der AMP-Jahreskonferenz 2019 einen neuen NGS-Workflow für die simultane DNA- und RNA-Analyse zum Einsatz im Krebs-Profiling vor
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Erweiterung seines QIAseg-NGS-Portfolios bekannt. Das Unternehmen bietet künftig einen eintägigen Workflow für die simultane
![The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019
The Medicines Company (NASDAQ:MDCO) today announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science
![Charles River Laboratories Announces Third-Quarter 2019 Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Charles River Laboratories Announces Third-Quarter 2019 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2019. For the quarter, revenue was $668.0 million, an increase of 14.1% from $585.3
![Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic
![Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company discovering and developing a pipeline of novel drug candidates targeting ion channels, announced today
![Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/
Dr. Howard Mayer, Executive Vice-President and Head
![Clovis Oncology Announces Third Quarter 2019 Operating Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Clovis Oncology Announces Third Quarter 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2019, and provided an update on Clovis’ clinical development programs and regulatory and
![Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will
![Sangamo Therapeutics Announces New Scientific Advisory Board](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Sangamo Therapeutics Announces New Scientific Advisory Board
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory Board (SAB). The SAB comprises an eclectic group of industry
![QIAGEN Expands Portfolio of Immuno-Oncology Assets for Future Companion Diagnostics and Biomarkers](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
QIAGEN Expands Portfolio of Immuno-Oncology Assets for Future Companion Diagnostics and Biomarkers
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a series of agreements that expand its immuno-oncology assets for future commercialization of novel companion diagnostics for
![QIAGEN Launches Novel NGS Workflow for Simultaneous DNA and RNA Analysis for Use in Cancer Profiling at 2019 AMP Annual Meeting](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
QIAGEN Launches Novel NGS Workflow for Simultaneous DNA and RNA Analysis for Use in Cancer Profiling at 2019 AMP Annual Meeting
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an expansion of its QIAseq NGS portfolio to offer a one-day workflow for simultaneous preparation of DNA and RNA libraries using
![QIAGEN erweitert sein Portfolio an Immuno-Onkologie-Lösungen für künftige Begleitdiagnostika und Biomarker](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
QIAGEN erweitert sein Portfolio an Immuno-Onkologie-Lösungen für künftige Begleitdiagnostika und Biomarker
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute eine Reihe von Vereinbarungen bekannt, über die es sein Portfolio an Immuno-Onkologie-Lösungen für die künftige Kommerzialisierung neuer
![Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31
![Savara Reports Third Quarter 2019 Financial Results and Provides Business Update](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Savara Reports Third Quarter 2019 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2019 and provided a business update.
“Based on the totality
![Sensorion Announces an Oral Presentation of New SENS-401 Preclinical Data at ISIET 2019 in Hannover](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Sensorion Announces an Oral Presentation of New SENS-401 Preclinical Data at ISIET 2019 in Hannover
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and
![Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and
![InflaRx knallt nach Daten-Update – NBC im Partyrausch](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
InflaRx knallt nach Daten-Update – NBC im Partyrausch
Der „goldene Herbst“ liefert: Nach +400% Kursgewinn mit IVERIC bio (WKN: A2PHLF) schießt mit InflaRx (WKN: A2H7A5) nun ein weiterer NBC-Favorit durch die Decke. Im After-Hours-Handel ging es gestern
![Evotec: Böses Zahlen-Déjà-Vu wie am 14. August?](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Evotec: Böses Zahlen-Déjà-Vu wie am 14. August?
Bald gibt es Zahlen: Am 12. November (Dienstag nächste Woche) wird Evotec SE (WKN: 566480) über die ersten neun Monate 2019 berichten. Die traditionelle Telefonkonferenz findet um 14:00 Uhr statt
![Epigenomics: Management steht das Wasser bis zum Hals!](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Epigenomics: Management steht das Wasser bis zum Hals!
Nach dem Kursdesaster vom Montag – die Aktie stürzte unter 1 Euro – sind die Verantwortlichen bei Epigenomics (WKN: A11QW5) alarmiert und beruhigen den Markt mit einer extra lancierten Pressemeldung
![IVERIC bio: Warum +370% erst der Anfang sein könnten](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
IVERIC bio: Warum +370% erst der Anfang sein könnten
Mitglieder des hochexklusiven No Brainer Clubs feiern weiter die Aktie von IVERIC bio (WKN: A2PHLF). Innerhalb der letzten zwei Wochen ging es für den Augenspezialisten an der Börse um zeitweise
![No Brainer Club: Weiter geht’s mit +126% Kursgewinn](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
No Brainer Club: Weiter geht’s mit +126% Kursgewinn
Es ist das, was unserere Experten als den „goldenen Herbst“ bereits vor Wochen angekündigt hatten: Ab Ende Oktober steigen bei den Top-Favoriten des No Brainer Clubs die Kurspartys. Ein Wert sticht
![MorphoSys: Gestern „bad news“ – heute „good news“](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
MorphoSys: Gestern „bad news“ – heute „good news“
Zu den größten Gewinnern am deutschen Aktienmarkt zählt heute eine Aktie, die gestern zunächst noch zu den größten Verlierern zählte, nämlich das Papier des Martinsrieder Biotechunternehmens MorphoS
![MorphoSys: Riesenenttäuschung – wer wusste da mehr?](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
MorphoSys: Riesenenttäuschung – wer wusste da mehr?
Zu den größten Verlierern am deutschen Aktienmarkt zählte heute früh das Papier des Biotechnologieunternehmens MorphoSys (WKN: 663200). Grund hierfür ist eine bereits gestern, am späten Abend
![IVERIC bio: No Brainer Club feiert nächste +100%-Party!](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
IVERIC bio: No Brainer Club feiert nächste +100%-Party!
Der weltweit einzigartige No Brainer Club feiert seinen nächsten Verdoppler: IVERIC bio (WKN: A2PHLF) liefert heute positive Studienergebnisse – das Papier klettert heute um mehr als +100% in die